Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
62.81
-5.15 (-7.58%)
Mar 31, 2025, 9:47 AM EDT - Market open
Arcellx Revenue
In the year 2024, Arcellx had annual revenue of $107.94M, down -2.16%. Arcellx had revenue of $15.27M in the quarter ending December 31, 2024, a decrease of -75.83%.
Revenue (ttm)
$107.94M
Revenue Growth
-2.16%
P/S Ratio
33.73
Revenue / Employee
$662,184
Employees
163
Market Cap
3.45B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ACLX News
- 10 days ago - Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - Business Wire
- 13 days ago - Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month - GlobeNewsWire
- 13 days ago - Arcellx Impressive Safety Data Leaves Doubts - Seeking Alpha
- 4 weeks ago - Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - Business Wire
- 4 weeks ago - Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 4 months ago - Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - Benzinga
- 4 months ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Business Wire
- 5 months ago - Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - Business Wire